North America Stroke Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Stroke Market Analysis

The North America stroke market is a rapidly growing sector within the healthcare industry, focused on products and services aimed at preventing, diagnosing, treating, and rehabilitating stroke patients. Key components in this market include pharmaceuticals (such as thrombolytics, antiplatelet agents, and anticoagulants), medical devices (like vascular stents and neuroprotective devices), and rehabilitation equipment (including physical therapy tools and speech therapy aids). Growth is driven by factors such as increasing awareness of stroke prevention, advancements in medical technology, and a rising geriatric population that is more susceptible to stroke. The increasing prevalence of non-communicable diseases, particularly hypertension and diabetes, further contributes to the demand for effective stroke care.

Stroke Market Size

The North America stroke market is expected to reach USD 23.96 billion by 2032 from USD 13.25 billion in 2024, growing at a CAGR of 8.0% in the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Stroke Market Trends

“Increasing adoption of advanced neuroimaging technologies and telemedicine solutions for stroke diagnosis and management”

One notable trend in the North America stroke market is the increasing adoption of advanced neuroimaging technologies and telemedicine solutions for stroke diagnosis and management. As awareness around the critical importance of rapid intervention in stroke treatment grows, there is a significant shift towards utilizing sophisticated imaging techniques, such as MRI and CT scans, which enable quicker and more accurate diagnosis of stroke types. In addition, telemedicine is becoming integral in providing timely consultations and remote monitoring, particularly in rural or underserved areas, allowing healthcare professionals to assess patients and initiate treatments promptly. This trend not only enhances patient outcomes but also drives innovation and investment within the stroke care continuum.

Report Scope and Stroke Market Segmentation       

Stroke Market Definition

The North America stroke market encompasses the various products, services, and technologies involved in the prevention, diagnosis, treatment, and rehabilitation of stroke patients worldwide. This includes a range of medical devices, pharmaceuticals, imaging equipment, and therapeutic solutions aimed at addressing the complexities of stroke care. The market is driven by the rising incidence of stroke due to aging populations, lifestyle factors, and increased awareness of stroke symptoms and treatment options. In addition, advancements in healthcare technologies and telemedicine are shaping the landscape, facilitating better patient management and improving outcomes in stroke care across diverse demographics and healthcare settings.

Stroke Market Dynamics

Drivers

• Rising Incidences of Stroke Drive Demand for Treatments

The rising incidence of stroke is a significant driver in the stroke market, influencing both the demand for treatment and healthcare infrastructure. Stroke, a leading cause of disability and death worldwide, is increasingly common due to various risk factors, including aging populations, sedentary lifestyles, high blood pressure, diabetes, smoking, and poor diet. As life expectancy increases and populations age, the prevalence of conditions that contribute to stroke, such as hypertension and atrial fibrillation, has also risen, resulting in more people suffering from strokes and requiring immediate medical attention and long-term rehabilitation.

 For instance,

In May 2023, according to the article published in eClinicalMedicine, stroke the second leading cause of death and third leading cause of disability worldwide. Over the past 30 years, there has been an increase in the absolute number of incident (70%) and prevalent (85%) strokes, as well as deaths (43%) from stroke.

• Increasing Number of Patients with Hypertension and Coronary Heart Diseases

Hypertension, commonly known as high blood pressure, is a medical condition characterized by elevated force of blood against the walls of arteries. It is typically defined by a blood pressure reading of 130/80 mm Hg or higher and can be categorized as either essential (primary) or secondary, depending on its underlying cause. Prolonged hypertension can lead to a range of serious health issues, with one of the most significant being coronary heart disease. Coronary heart disease, also known as coronary artery disease, results from the gradual accumulation of fatty deposits (atherosclerosis) in the coronary arteries, which supply oxygen and nutrients to the heart muscle. As these arteries narrow or become blocked, blood flow to the heart is reduced, leading to chest pain (angina) and, in severe cases, heart attacks.

For instance,

In September 2023, according to an article published in Pan American Health Organization Journal, Hypertension, often asymptomatic, significantly contributes to cardiovascular diseases, which are the leading cause of death. Factors such as aging, obesity, and poor lifestyle choices are fueling the rising prevalence, demanding effective treatments.

Opportunities

• Development of Advanced Therapeutics for Strokes

The development of advanced therapeutics presents a significant opportunity for the stroke market by addressing the substantial unmet needs in stroke care. Current treatments, primarily focused on restoring blood flow through thrombolysis or thrombectomy, are effective only within a narrow time window and do not address the underlying neuronal damage. Advanced therapeutics, such as neuroprotective agents, cell-based therapies, and targeted drug delivery systems, promise to mitigate this damage, promote neuronal repair, and improve long-term functional outcomes for stroke patients. This will lead to a decrease in disability, reduced healthcare costs associated with long-term care, and improved quality of life for survivors, thus expanding the market potential by attracting investment and driving demand for more effective treatments.

For instance,

In April 2022, according to an article published by the American Heart Association Journals, the treatment of acute ischemic stroke continues to advance. Tenecteplase has been evaluated as an alternative thrombolytic drug and evidence suggests that it is as least as effective as alteplase and may lyse large vessel clots more effectively. Endovascular therapy with mechanical thrombectomy has now been shown to be beneficial up to 24 hours after stroke onset in carefully selected patients with proximal, large vessel occlusions.

• Expansion in Stroke Rehabilitation Services

The expansion of stroke rehabilitation services presents a substantial opportunity for the stroke market by addressing the growing need for more effective recovery and rehabilitation programs. Currently, stroke survivors often face significant challenges in regaining lost motor and cognitive functions, leading to prolonged hospital stays, increased medical costs, and reduced quality of life. As the global population ages and stroke incidence rates rise, there is a pressing need for enhanced rehabilitation services that cater to the individual needs of stroke survivors. By expanding stroke rehabilitation services, healthcare providers and payers can address the unmet demand for comprehensive and personalized care, leading to better patient outcomes, reduced healthcare costs, and increased patient satisfaction.

For instance,

In April 2023, according to an article published by the MDPI, developed countries make efforts to provide rehabilitation for stroke patients. Physical rehabilitation can reduce or prevent known complications in stroke patients while also improving their quality of life. Therapists choose interventions based on impairments, activity limitations, and goals of recovery.

Restraints/Challenges

• High Cost of Diagnosis

Heart disease and stroke are one of the major factors of increasing mortality rate globally over the years. Stroke can be ranked among the most costly chronic diseases. More than 868,000 Americans die due to heart disease or stroke every year—that’s one-third of all deaths. With the increasing incidence of stroke, the cost of diagnosis and treatment has increased over the years which is the major restraining factor.

The majority of patients not only endure life-long disabilities that affect their livelihood but also have an enormous societal economic impact. The cost of diagnosis has also increased with the rise in technological advancement.

For instance,

According to the Agency for Healthcare Research and Quality, the average hospital admission for ischemic stroke (which includes diagnosis & stay) is 5.6 days at USD 9,100 per stay, and for hemorrhagic stroke, it is 8.4 days at USD 19,500 per stay.

• Increase in Product Recall

A wide range of diagnostic devices for stroke are used by professionals for performing different procedures on various patients of different age groups. Thus, side effects and complications associated with the use of these devices can cause serious harm to the patients.

Also these diagnostic devices and products are very expensive and highly risky for which a potential failure may cause serious consequences to the patient. Therefore, they are strictly regulated and recalled for the safety of patients.

For instance,

Neusoft Medical Systems Co., Ltd. Company’s product NeuViz 64 Multi-slice CT Scanner System Product which is a Multi-Slice CT Scanner System used as a whole body computed tomography x-ray system featuring a continuously rotating x-ray tube and detector array have been recalled by FDA due to the software error into the system.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Stroke Market Scope

The market is categorized into five notable segments based on type, diagnosis and treatment, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Ischemic Stroke
  • Thrombotic (Cerebral Thrombosis)
  • Embolic (Cerebral Embolism)
• Hemorrhagic Stroke
  • Subarachnoid Hemorrhage
  • Intracerebral Hemorrhage
• Transient Ischemic Attact (TIA)

Diagnostic & Treatment

• Treatment
  • Medication
    •  By Class
      • Blood Pressure Medicines
        • Angiotensin-Converting Enzyme (ACE) Inhibitors
          • Ramipril
          • Lisinopril
          • Enalapril
          • Perindopril
          • Other
        • Thiazide Diuretics
          • Indapamide
          • Bendroflumethiazide
          • Spironolactone
          • Amiloride
          • Other
        • Calcium Channel Blockers
          • Amlodipine
          • Nifedipine
          • Verapamil
          • Nicardipine
          • Felodipine
          • Nimodipine
          • Other
        • Beta Blockers
          • Atenolol
          • Bisoprolol
          • Labetolol
          • Others
        • Alpha-Blockers
          • Doxazosin
          • Others
        • Others
      • Antiplatelet Drugs
        • Aspirin
        • Clopidogrel
        • Dipyridamole
        • Ticlopidine
        • Others
      • Anticoagulants
        • Warfarin
        • Apixaban
        • Dabigatran
        • Heparin
        • Rivaroxaban
        • Other
      • Tissue Plasminogen Activator (TPA)
        • Alteplase
        • Tenecteplase
        • Reteplase
        • Anistreplase
        • Other
      • Statins
        • Atorvastatin
        • Simvastatin
        • Lovastatin
        • Rosuvastatin
        • Fluvastatin
        • Pravastatin
        • Pitavastatin
        • Others
      • Vitamin K
      • Supportive Medication
        • Nutritional Supplements
        • Antipyretics
        • Others
    •  By Drug Type
      • Branded
        • Activase
        • Edobaxan
        • Coumadin
        • Heparin Leo
        • Duoplavin
        • Aggrenox
        • Retavase
        • Jantoven
        • Cathflo
        • Other
    • Generic
      •  By Route of administration
        • Oral
          • Tablet
          • Capsules
          • Others
        • Parenteral
          • Intravenous
          • Subcutaneous
        • Others
      •  By Mode of Purchase
        • Prescription
        • Over the Counter (OTC)
      •  By Therapy Type
        • Combination Therapy
        • Monotherapy
    • Surgery
      • Embolic Coils
      • Aspiration Catheters
      • Stent Retriever
      • Surgical Clipping
      • Others
    • Others Therapy
      • Physical Therapy
      • Occupational Therapy
      • Speech Therapy
      • Others
  • Diagnosis
    • Imaging Test
      • Computerized Tomography (CT) Scan
      • Magnetic Resonance Imaging (MRI)
      • Carotid Ultrasound
      • Cerebral Angiogram
    • Blood Test
    • Echocardiogram
    • Lumbar Puncture
    • Others

Gender

• Female
• Male

End User

• Hospitals & Clinics
• Specialty Clinics
• Ambulatory Surgical Center
• Homecare
• Laboratories
• Others

Distribution Channel

• Direct
• Retail
• Online

Stroke Market Regional Analysis

The market is analyzed and market size insights and trends are provided by type, diagnosis & treatment, gender, end user, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, and Mexico

U.S. is expected to dominate and fastest growing country in the stroke market, driven by a high disease burden, urbanization, and expanding diagnostic and therapeutic access. Government focus on NCDs and private sector investment are accelerating market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Stroke Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Stroke Market Leaders Operating in the Market Are:

• Bristol-Myers Squibb Company (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• Bayer AG (Germany)
• Sandoz AG (Switzerland)
• Pfizer Inc. (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• Viatris Inc. (U.S.)
• AstraZeneca (U.K.)
• Penumbra, Inc. (U.S.)
• GLENMARK PHARMACEUTICALS LTD (India)
• Fresenius SE & Co. KGaA (Germany)
• Teva Pharmaceuticals USA, Inc. (Israel)
• Lupin (India)
• Amneal Pharmaceuticals LLC (U.S.)

Latest Developments in Stroke Market

• In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for the treatment of high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation and desire to change the landscape for patients with serious cardiovascular disease
• In September 2020, Daiichi Sankyo Company Limited announced that it has submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding. Risk. This application is based on the results of a Japanese Phase 3 clinical trial (ELDERCARE-AF trial) in 984 patients with non-valvular atrial fibrillation who are at least 80 years old and have a high risk of bleeding and are not suitable for other available anticoagulant therapies. Daiichi Sankyo plans to contribute to the treatment of elderly patients with non-valvular atrial fibrillation by offering a new treatment option
• In July 2022, Sandoz, the world's leading manufacturer of generics and biosimilars, announced an investment of approximately USD 90 million in its facility in Ljubljana, Slovenia, to establish its Sandoz Biopharma Development Center by 2026. With this investment, the Ljubljana site will become one of Sandoz's most important biosimilar product development sites. The new office will result in the creation of approximately 200 new full-time jobs and will further strengthen the company's capabilities in the development of biosimilars and pharmaceutical products
• In January 2023, Penumbra, Inc., a healthcare company focused on innovative therapies, announced the US Food and Drug Administration (FDA) approval and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's new Lightning Intelligent Aspiration technology, which now has two clot detection algorithms. Combined with innovative catheter technology, the Lightning Flash is designed to quickly remove large blood clots from the body, including venous embolism and Pulmonary Embolism (PE). This launch will help the company expand its product portfolio because the advanced results of this new technology are exceptionally traceable and its unique ability to differentiate flowing blood from clots
• In August 2023, Lupin has announced the launch of Jeet, a patient support program dedicated to heart health. The launch of the initiative coincides with India's 77th Independence Day, which symbolizes freedom from disease-related stress and the journey to a happier and healthier life. Jeet becomes a trusted partner in cardiovascular care by offering various benefits such as cost savings, medical assistance, medication reminders and lifestyle support. Jeet offers a holistic approach to improving the physician and patient experience by increasing awareness of cardiovascular disease and its comorbidities. The app includes features designed to encourage a healthier lifestyle and support a healthy heart

SKU-73764